TickerSparkInvestor Intelligence
Spark Generator
Stock Deep Dives
AI Analyst
Agentic Chat
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Spark Charts
AI Technical Analysis
The Feed
Today's Market Intel
Stock Reports
AI Research Reports
Top Stocks
AI-Curated Stock Lists
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
IPO Calendar
Upcoming Listings
Launch App
Log inCreate Account
← Back to TickerSpark
Earnings FlashTWSTHealthcareMedical - Diagnostics & Research

Twist Bioscience Corporation (TWST) drops on earnings misses

May 4, 20262 min read
Twist Bioscience Corporation (TWST) drops on earnings misses

Key Takeaway

Twist Bioscience Corporation (TWST) fell 5.50% after reporting a wider-than-expected quarterly loss, with EPS of -0.71 versus -0.54 expected. Revenue narrowly beat estimates at $0.11 billion, but the market focused on the second straight earnings miss and the lack of clear margin improvement.

Twist Bioscience Corporation (TWST) drops after earnings miss

Twist Bioscience Corporation (TWST) missed on EPS and narrowly beat on revenue, posting EPS of -0.71 versus -0.54 expected and revenue of $0.11B versus $0.11B expected, while the stock fell 5.50% in regular-session trading to $57.08.

Key Numbers

EPS: -0.71 vs -0.54 estimate, a miss.

Revenue: $0.11B vs $0.11B estimate, a beat.

Stock reaction: TWST closed at $57.08, down 5.50% in regular-session trading from the prior close of $60.40.

Intraday range: shares traded between $56.01 and $59.99.

Recent earnings trend: this follows a smaller EPS miss in the prior quarter, when TWST reported -0.50 versus -0.48 estimated on 2026-02-02.

Profit pressure outweighed the revenue beat

The market focused on profitability. Twist Bioscience beat on revenue, but the EPS miss was wider and landed after a prior-quarter miss as well. For a $3.5B growth company, that is usually enough to pressure the stock, especially when the top-line beat is only slight.

TickerSpark

Institutional-grade market intelligence for the retail investor. Stop guessing. Start winning.

Product

  • Spark Generator
  • AI Analyst
  • Plans

Research

  • The Feed
  • Stock Reports
  • Macro Updates
  • Blog

Company

  • About Us
  • Contact

Legal

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC. All rights reserved.

Made in Delaware, USA.

The recent pattern is mixed. Twist beat EPS in two of the three quarters before this report, but it has now missed in back-to-back quarters. That shifts attention back to cost control and operating leverage. In plain English, investors want revenue growth to turn into smaller losses, not bigger disappointment.

The 5.50% drop in regular-session trading shows the market treated this as a margin story, not a sales story. When a company clears the revenue bar but still gets sold, investors are usually telling management that execution below the gross line matters more right now.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started

Bottom Line

Twist Bioscience delivered enough revenue to edge past estimates, but the deeper EPS miss and a second straight quarterly shortfall sent TWST lower and kept the focus on profitability.

Read the full TWST research report

Frequently Asked Questions

+Why did Twist Bioscience stock drop after earnings?

Twist Bioscience Corporation (TWST) fell because its EPS miss was larger than expected, even though revenue slightly beat estimates. Investors focused on profitability, and the stock closed down 5.50% at $57.08.

+Did Twist Bioscience beat revenue and miss earnings in the latest quarter?

Yes. Twist Bioscience reported revenue of $0.11 billion versus $0.11 billion expected, but EPS came in at -0.71 compared with the -0.54 estimate. The market treated the earnings miss as the more important result.

+How much did TWST stock move after the earnings report?

TWST closed at $57.08, down 5.50% in regular-session trading from the prior close of $60.40. Shares traded between $56.01 and $59.99 during the session.

+What does Twist Bioscience's earnings miss mean for investors?

The report suggests investors are still waiting for revenue growth to translate into better operating leverage and smaller losses. With back-to-back EPS misses, the market is likely to stay focused on cost control and margin improvement.

Want the full picture on TWST?

Read the analyst-grade research report — charts, grades, and price targets.

Read the TWST reportGet Full Access

Get the full TWST research report

  • Analyst-grade deep dive
  • Charts, valuation, grades
  • Buy/sell price targets
Read the TWST report

Trade smarter with AI-powered research

  • Daily market intelligence
  • AI stock analysis reports
  • Real-time chat with an AI analyst
Get Full Access

Free trial · Cancel anytime

More on TWST

All articles
Twist Bioscience Corporation (TWST) drops after deep earnings miss
TWST

Twist Bioscience Corporation (TWST) drops after deep earnings miss

Twist Bioscience Corporation (TWST) drops despite revenue growth and raised guidance, as a wider-than-expected EPS loss overshadowed strong segment momentum, margin improvement, and continued sequential sales gains. This deep-dive breaks down the earnings miss, operating trends, and why investors focused on profitability over the top-line beat.

5/5/2026 10 min
Twist Bioscience (TWST): Margin Gains, But Valuation Is Rich
TWST

Twist Bioscience (TWST): Margin Gains, But Valuation Is Rich

Twist Bioscience is scaling revenue, expanding gross margin, and gaining traction in AI-enabled discovery, but the stock already prices in much of the progress. Our view is Hold as the company works toward profitability.

5/4/2026 22 min
Mortgage Rates Jump to 6.56% as Housing Momentum Fades

Mortgage Rates Jump to 6.56% as Housing Momentum Fades

The MBA’s 30-year mortgage rate climbed to 6.56%, its highest in seven weeks, as applications fell and purchase demand weakened. The rise underscores persistent affordability pressure, a fragile refinance market, and a housing sector still struggling to regain momentum amid higher borrowing costs.

5/20/2026 6 min